Houstonian Lindsay Huelse launched the number one wellness app for women.Photo courtesy of The FITT Cycle

Sticking to a fitness routine can be challenging — what with the myriad exercises, personal trainers, gyms, and apps. Creating a personalized program to fit specific goals, gain confidence, and take control of health concerns is what drove Houstonian Lindsay Huelse to launch a wildly popular female wellness app.

The FITT Cycle (which stands for Fasting, Intervals, and Target Training) app incorporates fitness routines, nutrition plans, accountability, community, and entrepreneurship.

"Historically, fitness apps are great for memberships," Huelse tells CultureMap. "I wanted to create a platform for returning clients where they could have stability and ditch the diets."

Since its launch in December 2019, Huelse says she has seen a membership growth of almost 2,000 percent, noting that there is no other app with The FITT Cycle's features. She calls it a hybrid of My Fitness Pal, the Peloton App, Facebook communities, and more.

"Everything is in one place," she adds.

The app combines exercise and diet to make for a more complete health tracking app than existing technology. Photo courtesy of The FITT Cycle

A retired nurse, Huelse is now a certified nutrition coach and self-proclaimed "queen of carb cycling," a regimen that focuses on alternating daily carbohydrate intake to promote weight loss and overcome weight loss plateaus.

Fitness has always played a role in Huelse's life, both on and off the field. She played soccer competitively throughout high school and college but it wasn't until her pre-nursing track where she became intrigued by nutrition.

"It was something I didn't learn growing up," Huelse adds. "I was fascinated with fueling my body to help it function properly."

Upon graduation, she worked in the intensive care unit before retiring in 2018 from the corporate world of home health and hospice. As a geriatric nurse, she says she enjoyed educating the elderly on manageable ways to change their diet and reduce inflammation, something they're not always willing to do.

"This led me to be passionate about helping women with preventative measures to decrease inflammation and create food freedom," she says.

With multiple features, including carb cycling macros and an in-app nutrition tracker for weight loss success; daily workouts and targeted training for the home or gym; an in-app guide to intermittent fasting with a timer to indicate when the fasting window is complete; a community to keep members accountable; and a library of more than 250 recipes, The FITT Cycle app is truly customizable for your health, wellness, and fitness goals.

"As a woman who used to work out for hours at a time and follow a clean nutrition plan, I was gaining weight but couldn't understand why," she says. "There's a science to reaching your fitness goals and through learning about my clients who have children, are older, or are postmenopausal helped me design the app to show them you don't have to feel fatigued or struggle with losing weight."

Huelse adds that the last diet her clients followed will be the last diet they ever chase.

Every one of Huelse's clients who join The FITT Cycle app has the opportunity to earn a 50 percent commission for anyone they enroll in the app. Huelse says her vision for creating a cycle of entrepreneurship is to give back to her community and to those who helped her on her path to entrepreneurship.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.